|1.||Yu, Huang-Ping: 6 articles (07/2012 - 06/2007)|
|2.||Bland, Kirby I: 6 articles (12/2009 - 06/2007)|
|3.||Chaudry, Irshad H: 6 articles (12/2009 - 06/2007)|
|4.||Cohen, Michael V: 5 articles (10/2013 - 02/2003)|
|5.||Downey, James M: 5 articles (10/2013 - 02/2003)|
|6.||Hsu, Jun-Te: 5 articles (11/2012 - 10/2007)|
|7.||Hsieh, Chi-Hsun: 5 articles (07/2011 - 10/2007)|
|8.||Schwacha, Martin G: 5 articles (12/2009 - 06/2007)|
|9.||Choudhry, Mashkoor A: 5 articles (08/2009 - 06/2007)|
|10.||Yang, Xi-Ming: 4 articles (10/2013 - 01/2005)|
07/07/2004 - "Among the ten most promising derivatives, six demonstrated lower liver toxicity and greater promise for inhibition of tumor cell growth than the lead structure wortmannin."
01/15/2015 - "Pharmacogenomic and molecular docking studies on the cytotoxicity of the natural steroid wortmannin against multidrug-resistant tumor cells."
09/01/2007 - "The natural product, wortmannin, has been widely used to study the functional consequences of PI3K inhibition in both normal and transformed cells in culture but is not a suitable cancer chemotherapeutic agent due to stability and toxicity issues. "
05/01/2007 - "The objective of this study was to explore whether a specific inhibitor of PI3K, wortmannin, could potentiate the antitumor effect of radiation in vivo, particularly on radioresistant murine tumors. "
02/01/2001 - "Further studies are needed to compare the effects of wortmannin in human tumor cells and various normal cells including proliferative and quiescent cells."
03/30/2001 - "Pretreatment of transgenic hearts with wortmannin immediately before and during ischemia eliminated reperfusion-mediated activation of Akt and neutralized the resistance to apoptosis. "
01/01/2009 - "PI3K/Akt inhibitor wortmannin (100 nM) was administered 15 min prior to 30-min regional (left anterior descending coronary artery occlusion) ischemia for the study of ischemic arrhythmias in the hearts perfused at constant coronary flow or prior to 30-min global ischemia followed by 2-h reperfusion for the infarct size (IS) determination (tetrazolium staining) in the hearts perfused at constant pressure. "
01/01/2013 - "Administration of PI3K selective antagonist wortmannin inhibited the improvement of spatial learning memory and the increase of neurogenesis in the dentate gyrus up to 28 days post ischemia. "
08/01/2012 - "Fifty male SD rats were divided randomly into five groups: the control group (SH group), the ischemia reperfusion group (I/R group), the resveratol pretreatment group (Res group), the resveratol pretreatment + wortmannin group (Res +Wom group) and the ischemia reperfusion + wortmannin group (I/R + Wom group). "
01/01/2012 - "Since wortmannin treatment significantly reduces ROS production with ischemia, we investigated the role of phosphoinositide 3-kinase (PI3K) in shear-associated signaling. "
12/01/2006 - "Treatment with the PI3-K inhibitor wortmannin partially inhibited the fluvastatin-induced increases in phosphorylation of Akt and eNOS, and the decrease in translocation of PI3-K heterodimer to the membranes during sepsis was slightly improved by fluvastatin. "
07/01/2012 - "Wortmannin, which inhibits the Akt upstream regulator phosphatidylinositol 3-kinase, abrogated the protective effects of olprinone and corforsin daropate on sepsis-associated lung inflammation and apoptosis. "
06/01/2003 - "Wortmannin radiosensitization was observed in Chinese hamster cells (V79-B310H , CHO-K1), mouse mammary carcinoma cells (SR-1), transformed human fibroblast (N2KYSV), chicken B lymphocyte wild-type cells (DT40), and chicken Rad54 knockout cells (Rad54-/-). "
08/01/2004 - "In this study, we show that TPCK inhibits TRAIL-induced caspase activity but potentiates wortmannin-dependent caspase activity in prostatic carcinoma cell lines. "
01/15/1998 - "This study examined the effects of wortmannin and protein kinase C (PKC) inhibitors on HGF-mediated changes in metabolic activity in glomerular mesangial cells and renal epithelial carcinoma A498 cells. "
05/15/2001 - "ET-743 was more effective in cells lacking DNA-PK; moreover, pre-treatment of HCT-116 colon carcinoma cells with wortmannin, a potent inhibitor of DNA-PK, sensitized cells to ET-743. "
09/15/1998 - "In this study, we demonstrate that AKT2 is activated in response to stimulation by insulin in a dose- and time-dependent manner in human ovarian carcinoma cells and that activation of AKT2 is abolished in cells pretreated with wortmannin, an inhibitor of phosphatidylinositol 3-kinase (PI 3-kinase). "
03/20/2003 - "Despite its effects on induction of MycN and on progression through S phase, wortmannin did not block proliferation of neuroblastoma cells. "
05/01/2000 - "NBL-1, when added to the culture medium of the neuroblastoma cells, was incorporated by endocytosis in a wortmannin-sensitive manner. "
12/01/1999 - "In N2a neuroblastoma cells expressing either wild-type APP or the "Swedish" familial Alzheimer's disease-associated mutant variant of APP, wortmannin treatment resulted in decreased release of both Abeta and soluble APPalpha. "
06/01/2005 - "To investigate the effect of dishevelled-1 (DVL-1) on wortmannin-induced Alzheimer-like hyperphosphorylation of cytoskeletal proteins in mouse neuroblastoma 2a (N2a) cells. "
04/01/2004 - "Human neuroblastoma cells (SK-N-SH, BEC, LAN-1 and IMR-32) were treated with LY294002 or wortmannin, inhibitors of PI3K, for 24 hours. "
|1.||Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)
|2.||2- (4- morpholinyl)- 8- phenyl- 4H- 1- benzopyran- 4- one
|4.||DNA (Deoxyribonucleic Acid)
|6.||Insulin-Like Growth Factor I (IGF-1)
|9.||Small Interfering RNA (siRNA)
|1.||Heterologous Transplantation (Xenotransplantation)
|5.||Drug Therapy (Chemotherapy)